Insider Transactions in Q4 2024 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
1,091
-30.32%
|
$147,285
$135.0 P/Share
|
|
Dec 17
2024
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,091
+23.27%
|
$86,189
$79.02 P/Share
|
|
Nov 29
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,331
-13.11%
|
$293,706
$126.29 P/Share
|
|
Nov 29
2024
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,426
+19.93%
|
-
|
|
Nov 08
2024
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+5.52%
|
$624,325
$85.2 P/Share
|
|
Nov 04
2024
|
Stephen A Sherwin Director |
SELL
Bona fide gift
|
Direct |
2,000
-7.55%
|
-
|
|
Oct 03
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,295
-77.45%
|
$146,335
$113.66 P/Share
|